Energous (WATT) Stock Hits New High

NEW YORK (TheStreet) -- Energous  (WATT) rose more than 35% to a new high of $16 as of 12:40 p.m. on Monday after the tech company's strong debut after its IPO late last week.

The company priced its initial public offering at $6 a share and sold 4 million shares. Energous also included a 45-day option for underwriters to buy up to an additional 600,000 shares. If this happens, then gross proceeds from the IPO would total $27.6 million.

Energous is developing WattUp, a wire-free charging technology that would allow users to freely walk around with and use their mobile devices rather than have to leave them on a pad or other station to charge. The devices would charge through Wi-Fi, which could potentially revolutionize the business.

Must Read: Warren Buffett's 10 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

WATT Chart

WATT data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Apple Gains as U.S. China Trade Tensions Ease After Weekend Summit

Apple Gains as U.S. China Trade Tensions Ease After Weekend Summit

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI